Author Affiliations: Department of Microbiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.
We appreciate the comments raised by Zhang and Li regarding our article,1 presenting an overview of Th1/Th2 response to C jejuni antigen in patients in the progressive and recovery phases of GBS. Campylobacter jejuni infection is identified as a major triggering agent of GBS. Several studies also confirmed the association between C jejuni and axonal subtypes of GBS.2 Although there are conflicting reports, both subtypes, demyelinating (AIDP) and axonal, can follow C jejuni infection. We had earlier reported the stratified analyses that showed C jejuni (26%) was the most common preceding infection in our GBS cohort and had more frequent association with the axonal subtype than demyelinating subtype (41% vs 6%; P < .001). Further, antiganglioside antibodies were detected more frequently in patients with GBS than controls (81% vs 10%; P < .001), and a higher proportion of axonal cases had anti-GM1 antibodies than patients with AIDP (IgG: 65% vs 32%; P = .004 and IgM: 46% vs 29%; P = .05).2
Nyati KK, Verma A, Prasad KN. The Th1/Th2 Paradigm in Guillain-Barré Syndrome—Reply. Arch Neurol. 2011;68(9):1209–1210. doi:10.1001/archneurol.2011.215
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.